Related Experiment Video

Updated: Jun 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based

Boming Cao1, Jingyi Pei1, Ling Kong1

  • 1State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, National Chinmedomics Research Center, Metabolomics Laboratory, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Harbin, China.

Frontiers in Cardiovascular Medicine
|June 29, 2026
PubMed

Insights

Hypertension and dyslipidemia synergistically accelerate cardiovascular disease (CVD) through shared molecular pathways. Targeting these interconnected mechanisms offers a precision medicine approach for improved metabolic-vascular health.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Molecular Biology

Background:

  • Cardiovascular disease (CVD) is the leading global cause of death.
  • Hypertension and dyslipidemia often coexist, amplifying CVD risk through interconnected molecular pathways.

Purpose of the Study:

  • To systematically review the synergistic mechanisms linking hypertension and dyslipidemia to CVD progression.
  • To explore emerging multi-target therapies for managing these comorbid conditions.

Main Methods:

  • Systematic review of scientific literature.
  • Focus on key molecular pathways: RAAS/PPAR axis, AMPK/SIRT1 signaling, NLRP3 inflammasome.
  • Examination of current and emerging therapeutic strategies.

Main Results:

  • The interplay between hypertension and dyslipidemia disrupts endothelial function, increases oxidative stress, and promotes chronic inflammation.
  • These effects lead to vascular damage and atherosclerosis.
  • Combination therapies (e.g., RAAS inhibitors with statins) and novel agents show promise.

Conclusions:

  • A precision medicine framework is needed to address the synergistic pathophysiology of hypertension and dyslipidemia.
  • Pathway-integrated, personalized interventions can restore metabolic-vascular homeostasis and improve clinical outcomes.

Keywords:
cardiovascular diseasedyslipidemiahypertensioninflammationmolecular mechanismstargeted therapy

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...